ANIX VS SDC Stock Comparison

Performance

ANIX
10/100

ANIX returned -42.05% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

SDC
10/100

SDC returned -32.98% in the last 12 months. Based on SPY's performance of -7.17%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

ANIX
75/100

1 analysts offer 12-month price targets for ANIX. Together, they have an average target of 8, the most optimistic target put ANIX at 8 within 12-months and the most pessimistic has ANIX at 8.

SDC

"Analyst Price Targets" not found for SDC

Sentiment

ANIX
67/100

ANIX had a bullish sentiment score of 66.58% across Twitter and StockTwits over the last 12 months. It had an average of 1.57 posts, 0.29 comments, and 1.43 likes per day.

SDC
70/100

SDC had a bullish sentiment score of 69.85% across Twitter and StockTwits over the last 12 months. It had an average of 139.63 posts, 16,373.01 comments, and 17,465.68 likes per day.

Technicals

ANIX
11/100

ANIX receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

SDC
82/100

SDC receives a 82 of 100 based on 14 indicators. 11 are bullish, 2 are bearish.

Earnings

ANIX
61/100

ANIX has missed earnings 3 times in the last 20 quarters.

SDC
10/100

SDC has missed earnings 9 times in the last 20 quarters.

Profit

ANIX
10/100

Out of the last 20 quarters, ANIX has had 0 profitable quarters and has increased their profits year over year on 0 of them.

SDC
10/100

Out of the last 19 quarters, SDC has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

ANIX
34/100

ANIX has had a lower than average amount of volatility over the last 12 months giving it a score of 34 of 100.

SDC
50/100

SDC has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Anixa Biosciences, Inc. Summary

Nasdaq / ANIX

Healthcare

Biotechnology

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

SmileDirectClub, Inc. Class A Common Stock Summary

Nasdaq / SDC

Healthcare

Medical Instruments & Supplies

SmileDirectClub, Inc., an oral care company, offers clear aligner therapy treatment. The company manages the end-to-end process, which include marketing, aligner manufacturing, fulfillment, treatment by a doctor, and monitoring through completion of their treatment with a network of approximately 250 licensed orthodontists and general dentists through its teledentistry platform, SmileCheck in the United States, Puerto Rico, Canada, Australia, the United Kingdom, New Zealand, Ireland, Hong Kong, Germany, Singapore, France, Spain, and Austria. It also offers aligners, impression and whitening kits, whitening gels, and retainers; and toothbrushes, toothpastes, water flossers, SmileSpa, and various ancillary oral care products. The company was founded in 2014 and is headquartered in Nashville, Tennessee.

Power up your portfolio